Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Leuk Lymphoma. 2018 Dec;59(12):3016-3017. doi: 10.1080/10428194.2018.1457149. Epub 2018 May 24.

Authors

Connie Cheng¹, Daniel Woronow¹, Afrouz Nayernama¹, Tanya Wroblewski², S Christopher Jones¹

Affiliations

¹ a Division of Pharmacovigilance, Office of Surveillance and Epidemiology , Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring , MD , USA.
² b Division of Hematology Products, Office of Hematology and Oncology Products , Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring , MD , USA.

PMID: 29792382
DOI: 10.1080/10428194.2018.1457149

No abstract available

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Adverse Drug Reaction Reporting Systems / statistics & numerical data*
Aged
Arrhythmias, Cardiac / chemically induced
Arrhythmias, Cardiac / epidemiology*
Drug Monitoring / statistics & numerical data
Female
Humans
Incidence
Lymphoproliferative Disorders / drug therapy*
Male
Middle Aged
Piperidines
Pyrazoles / adverse effects*
Pyrimidines / adverse effects*
Treatment Outcome
United States
United States Food and Drug Administration / statistics & numerical data*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine